Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men - PubMed (original) (raw)
Clinical Trial
Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
E Näslund et al. Am J Clin Nutr. 1998 Sep.
Abstract
The gut peptide glucagon-like peptide 1(7-36) amide (GLP-1) is released into the circulation after food intake. GLP-1 has been shown to have an incretin effect and inhibits gastrointestinal motility in humans. In rats, intracerebral administration of GLP-1 results in reduced food intake. Obese humans have been found to have an attenuated plasma GLP-1 response to a mixed meal. To approximate the physiologic state, GLP-1 or saline was administered intravenously and randomly at the beginning of a test meal served on a universal eating monitor to 6 obese subjects to test our hypothesis that GLP-1 influences termination of food intake (and thus food intake during a meal) and feelings of satiety in humans. As a marker for gastric emptying, 1.5 g acetaminophen was given at the start of the meal. Blood samples for analysis of acetaminophen, insulin, glucose, glucagon, and C-peptide were obtained. Hunger, fullness, and food choice were assessed with visual analogue scales and food-choice questionnaires. GLP-1 infusion resulted in a prolonged period of reduced feelings of hunger, desire to eat, and prospective consumption after the meal. The rate of gastric emptying was slower during infusion of GLP-1. Postprandial blood glucose concentrations were reduced during the GLP-1 infusion, but the amount of energy consumed, eating rate, and plasma concentrations of insulin, glucagon, and C-peptide were unchanged. GLP-1 given exogenously at the start of a meal did not seem to affect meal termination or the amount of food eaten. However, postprandial feelings of hunger decreased, suggesting that exogenous GLP-1 may influence feelings of hunger and satiety in humans.
Similar articles
- No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ, Morgan LM. Long SJ, et al. Br J Nutr. 1999 Apr;81(4):273-9. Br J Nutr. 1999. PMID: 10999014 Clinical Trial. - Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S, Hellström PM. Näslund E, et al. Int J Obes Relat Metab Disord. 1999 Mar;23(3):304-11. doi: 10.1038/sj.ijo.0800818. Int J Obes Relat Metab Disord. 1999. PMID: 10193877 Clinical Trial. - Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Nauck MA, et al. Am J Physiol. 1997 Nov;273(5):E981-8. doi: 10.1152/ajpendo.1997.273.5.E981. Am J Physiol. 1997. PMID: 9374685 Clinical Trial. - Is glucagon-like peptide 1 an incretin hormone?
Nauck MA. Nauck MA. Diabetologia. 1999 Mar;42(3):373-9. doi: 10.1007/s001250051165. Diabetologia. 1999. PMID: 10096792 Review. - Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.
Nauck MA. Nauck MA. Acta Diabetol. 1998 Oct;35(3):117-29. doi: 10.1007/s005920050116. Acta Diabetol. 1998. PMID: 9840447 Review.
Cited by
- A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
Samson SL, Garber AJ. Samson SL, et al. Curr Diab Rep. 2016 Dec;16(12):120. doi: 10.1007/s11892-016-0823-6. Curr Diab Rep. 2016. PMID: 27766579 Review. - Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.
Novikoff A, Müller TD. Novikoff A, et al. Physiology (Bethesda). 2024 May 1;39(3):142-156. doi: 10.1152/physiol.00032.2023. Epub 2024 Feb 14. Physiology (Bethesda). 2024. PMID: 38353610 Review. - Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?
Bose M, Oliván B, Teixeira J, Pi-Sunyer FX, Laferrère B. Bose M, et al. Obes Surg. 2009 Feb;19(2):217-229. doi: 10.1007/s11695-008-9696-3. Epub 2008 Sep 27. Obes Surg. 2009. PMID: 18820978 Free PMC article. Review. - The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.
Barnett AH. Barnett AH. Diabetes Obes Metab. 2012 Apr;14(4):304-14. doi: 10.1111/j.1463-1326.2011.01523.x. Epub 2011 Dec 22. Diabetes Obes Metab. 2012. PMID: 22051096 Free PMC article. Review. - GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
Gilbert MP, Pratley RE. Gilbert MP, et al. Front Endocrinol (Lausanne). 2020 Apr 3;11:178. doi: 10.3389/fendo.2020.00178. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32308645 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials